A Bioavailability Study of LY2452473 and Tadalafil
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This study compares LY2452473 taken orally as a 5 milligram (mg) capsule at the same time as
a 5 mg tadalafil tablet with three different combination tablets (LY900010) of 5 mg LY2452473
and 5 mg tadalafil taken orally. The study will evaluate the amount of LY2452473 and
tadalafil circulating in the blood for each treatment. Side effects will be documented. This
study is approximately 34 days not including screening.